Carolyn Starrett joins NeoGenomics (NEO) board, expanding oncology and AI expertise
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
NeoGenomics, Inc. filed a current report announcing that its Board of Directors increased in size from nine to ten members and appointed Carolyn S. Starrett as a new director, effective immediately. She will serve until the 2027 annual meeting of stockholders and then until a successor is elected and qualified.
Starrett brings more than 25 years of experience in data, technology, and oncology, including executive roles at Flatiron Health, where she served as CEO and Board Director, and prior board service at Foundation Medicine. NeoGenomics highlights her expertise in real-world data, AI, and analytics to support its oncology diagnostics and precision medicine strategy.
Positive
- None.
Negative
- None.
8-K Event Classification
3 items: 5.02, 7.01, 9.01
3 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Board size after change: 10 directors
Term endpoint: 2027 annual meeting
Experience duration: over 25 years
+2 more
5 metrics
Board size after change
10 directors
Board increased from nine to ten members
Term endpoint
2027 annual meeting
Starrett’s board term runs until 2027 meeting
Experience duration
over 25 years
Starrett’s commercial, product, and operations experience
Flatiron Health tenure
2016 to 2026
Period Starrett worked at Flatiron Health
Flatiron CEO period
April 2021 to September 2025
Starrett’s tenure as CEO and Board Director at Flatiron
Key Terms
Board of Directors, independent director, precision medicine, forward-looking statements, +2 more
6 terms
Board of Directors financial
"the Board of Directors (the "Board") of NeoGenomics, Inc."
The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.
independent director financial
"compensation for her service as an independent director consistent with the Company's director compensation program"
An independent director is a member of a company's board of directors who is not involved in the company's day-to-day operations and has no significant relationships with the company that could influence their judgment. Their role is to provide unbiased oversight and ensure the company is managed in the best interests of all shareholders. This helps build trust and confidence among investors by promoting transparency and accountability.
precision medicine financial
"a leading provider of oncology diagnostic solutions that enable precision medicine"
Precision medicine uses a person’s unique genetic makeup, lifestyle and environment to choose treatments and preventive steps that are more likely to work for them than one-size-fits-all approaches. For investors, it matters because it can make therapies more effective and efficient—think tailoring a suit rather than buying off the rack—affecting drug development costs, market size, pricing power and the speed at which therapies win regulatory approval.
forward-looking statements regulatory
"This press release includes forward-looking statements."
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
real-world data technical
"experience using real-world data and analytics to help accelerate improvements in cancer care"
Real-world data consists of information collected from everyday sources outside of controlled experiments or official reports, such as patient records, insurance claims, or wearable device readings. For investors, it provides a more complete picture of how products and services perform in actual use, helping them make better-informed decisions based on how things work in real life rather than just in theory or controlled settings.
CAP-accredited and CLIA-certified laboratories technical
"operates a network of CAP- accredited and CLIA-certified laboratories"
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||||||||||||
| (Address of principal executive offices) | (Zip Code) | ||||||||||
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||||||||
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||||||||
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||||||||
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||||||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. | ||||
On June 23, 2026, the Board of Directors (the "Board") of NeoGenomics, Inc. (the "Company") increased the size of the Board from nine to ten directors and appointed Carolyn S. Starrett as a director to fill the newly created vacancy, effective immediately.
Ms. Starrett will serve as a member of the Board until the 2027 annual meeting of stockholders of the Company and until her successor is duly elected and qualified (or, if earlier, her resignation or removal). Ms. Starrett will receive compensation for her service as an independent director consistent with the Company's director compensation program as previously disclosed in the Company's definitive proxy statement for its 2026 annual meeting of stockholders.
| Item 7.01 | Regulation FD Disclosure | ||||
On June 25, 2026, the Company issued a press release regarding the appointment of Ms. Starrett to the Board, which is attached to the Current Report on Form 8-K as Exhibit 99.1.
This information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
| Item 9.01 | Financial Statements and Exhibits. | ||||
(a) | Not applicable | |||||||
(b) | Not applicable | |||||||
(c) | Not applicable | |||||||
(d) | Exhibits. | |||||||
99.1 | Press Release of NeoGenomics, Inc. dated June 25, 2026 | |||||||
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| NEOGENOMICS, INC. | |||||||||||||||||
| Date: | June 25, 2026 | By: | /s/ Alicia C. Olivo | ||||||||||||||
| Name: | Alicia C. Olivo | ||||||||||||||||
| Title: | Executive Vice President, General Counsel & Secretary | ||||||||||||||||
June 25, 2026 |  | ||||
NeoGenomics Appoints Carolyn Starrett to its Board of Directors
FORT MYERS, Fla.--(BUSINESS WIRE)-- NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the appointment of Carolyn Starrett to its Board of Directors.
Ms. Starrett brings over 25 years of commercial, product, and operations experience at data and technology companies and a deep understanding of AI and data insights in cancer care and research. She spent the last ten years from 2016 to 2026 at Flatiron Health serving in a variety of executive roles and ultimately leading the company as CEO and Board Director from April 2021 to September 2025. She is currently the President of Starrett Advisory, an independent consulting and strategic advisory firm, working with clients on strategic topics at the intersection of healthcare delivery, drug development, data, and AI.
“We are very excited to welcome Carolyn to the NeoGenomics board,” said Lynn Tetrault, Chair of the Board of NeoGenomics. “Carolyn’s experience using real-world data and analytics to help accelerate improvements in cancer care and treatment will serve us well as we continue to expand our portfolio and impact for cancer patients. I look forward to her insights and guidance.”
Ms. Starrett served as a Board Director at Foundation Medicine from 2021-2024. Prior to joining Flatiron, Ms. Starrett held several leadership roles at a predictive analytics company and led strategy and transformation efforts with healthcare and technology companies as a principal with Boston Consulting Group. She holds an MBA from the Kellogg School of Management at Northwestern University and a bachelor's degree from Brown University.
“I am honored to join NeoGenomics’ board at an exciting time in the company’s evolution,” said Ms. Starrett. “Neo’s growing portfolio of oncology diagnostics – paired with the new possibilities and insights enabled by AI – create a real opportunity to improve cancer care for patients, and I look forward to contributing to this next phase of innovation.”
About NeoGenomics
NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to deliver timely, actionable insights that guide personalized care decisions. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-
accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service sample-processing laboratory in Cambridge, England.
Forward Looking Statements
This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “could,” “would,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” “guidance,” “plan,” “potential” and other words of similar meaning, although not all forward-looking statements include these words. These forward-looking statements address various matters, including statements regarding the Company’s strategy, planned future operations and development plans and initiatives, as well as the timing, outcome and potential for its offerings to deliver higher sensitivity results with faster turnaround times compared to currently available assays, and the potential impact on clinical treatment and patient prognosis. Applicable risks and uncertainties include, among others, the Company’s ability to successfully complete development of and to offer new types of tests, to execute on its strategic priorities and to otherwise implement its business plan, and the risks identified under the heading "Risk Factors" contained in the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and the Company's other filings with the Securities and Exchange Commission.
We caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document (unless another date is indicated), and we undertake no obligation to update or revise any of these statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.
Media Contact
Andrea Sampson asampson@sampsonprgroup.com
Investor Contact
InvestorRelations@neogenomics.com
Source: NeoGenomics, Inc.
FAQ
What board change did NeoGenomics (NEO) disclose in this 8-K filing?
NeoGenomics disclosed that its Board of Directors expanded from nine to ten members and appointed Carolyn S. Starrett as a new director, effective immediately. She will serve until the 2027 annual meeting of stockholders and then until a successor is elected and qualified.
Who is Carolyn Starrett and what experience does she bring to NeoGenomics (NEO)?
Carolyn Starrett has over 25 years of commercial, product, and operations experience at data and technology companies. She previously held multiple executive roles at Flatiron Health, serving as CEO and Board Director, and also served on the board of Foundation Medicine, focusing on oncology and data-driven care.
How does Carolyn Starrett’s background align with NeoGenomics’ oncology diagnostics focus?
Starrett has deep experience using real-world data, analytics, and AI to advance cancer care and research. NeoGenomics emphasizes that her background at Flatiron Health and in predictive analytics aligns with its oncology diagnostics and precision medicine portfolio, supporting data-driven improvements in patient treatment decisions.
How will Carolyn Starrett be compensated as a NeoGenomics (NEO) director?
The filing states that Ms. Starrett will receive compensation consistent with NeoGenomics’ existing director compensation program, as described in its 2026 definitive proxy statement. This indicates she will be paid under the same structure as other independent directors, rather than a customized arrangement.
What forward-looking statements does NeoGenomics highlight in the press release?
NeoGenomics includes forward-looking statements about its strategy, planned operations, development initiatives, and expectations for test performance and clinical impact. It notes these statements involve risks and uncertainties described in its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and other SEC filings.
What is NeoGenomics’ core business as described in this release?
NeoGenomics describes itself as a premier cancer diagnostics company specializing in cancer genetics testing and information services. It offers an extensive oncology-focused testing menu and operates CAP-accredited and CLIA-certified laboratories in the United States and a CAP-accredited lab in Cambridge, England.